199 related articles for article (PubMed ID: 25850884)
1. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.
Blaes J; Thomé CM; Pfenning PN; Rübmann P; Sahm F; Wick A; Bunse T; Schmenger T; Sykora J; von Deimling A; Wiestler B; Merz C; Jugold M; Haberkorn U; Abdollahi A; Debus J; Gieffers C; Kunz C; Bendszus M; Kluge M; Platten M; Fricke H; Wick W; Lemke D
Mol Cancer Res; 2018 May; 16(5):767-776. PubMed ID: 29453321
[TBL] [Abstract][Full Text] [Related]
3. Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions.
Hartmann N; Messmann JJ; Leithäuser F; Weiswange M; Kluge M; Fricke H; Debatin KM; Strauss G
Blood; 2013 Jan; 121(3):556-65. PubMed ID: 23203823
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models.
Quijano-Rubio C; Silginer M; Weller M
J Neurooncol; 2022 Nov; 160(2):299-310. PubMed ID: 36355258
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients.
Tuettenberg J; Seiz M; Debatin KM; Hollburg W; von Staden M; Thiemann M; Hareng B; Fricke H; Kunz C
Int Immunopharmacol; 2012 May; 13(1):93-100. PubMed ID: 22446296
[TBL] [Abstract][Full Text] [Related]
6. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma.
Wick W; Fricke H; Junge K; Kobyakov G; Martens T; Heese O; Wiestler B; Schliesser MG; von Deimling A; Pichler J; Vetlova E; Harting I; Debus J; Hartmann C; Kunz C; Platten M; Bendszus M; Combs SE
Clin Cancer Res; 2014 Dec; 20(24):6304-13. PubMed ID: 25338498
[TBL] [Abstract][Full Text] [Related]
7. Yes and PI3K bind CD95 to signal invasion of glioblastoma.
Kleber S; Sancho-Martinez I; Wiestler B; Beisel A; Gieffers C; Hill O; Thiemann M; Mueller W; Sykora J; Kuhn A; Schreglmann N; Letellier E; Zuliani C; Klussmann S; Teodorczyk M; Gröne HJ; Ganten TM; Sültmann H; Tüttenberg J; von Deimling A; Regnier-Vigouroux A; Herold-Mende C; Martin-Villalba A
Cancer Cell; 2008 Mar; 13(3):235-48. PubMed ID: 18328427
[TBL] [Abstract][Full Text] [Related]
8. APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.
Raimbault A; Pierre-Eugene C; Rouquette A; Deudon C; Willems L; Chapuis N; Mathis S; Kunz C; Fricke H; Kosmider O; Bardet V; Fontenay M;
Oncotarget; 2016 Mar; 7(12):14898-911. PubMed ID: 26910909
[TBL] [Abstract][Full Text] [Related]
9. CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells.
Drachsler M; Kleber S; Mateos A; Volk K; Mohr N; Chen S; Cirovic B; Tüttenberg J; Gieffers C; Sykora J; Wirtz CR; Mueller W; Synowitz M; Martin-Villalba A
Cell Death Dis; 2016 Apr; 7(4):e2209. PubMed ID: 27124583
[TBL] [Abstract][Full Text] [Related]
10. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
Pohl U; Wagenknecht B; Naumann U; Weller M
Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
[TBL] [Abstract][Full Text] [Related]
11. CD95 ligand: lethal weapon against malignant glioma?
Weller M; Kleihues P; Dichgans J; Ohgaki H
Brain Pathol; 1998 Apr; 8(2):285-93. PubMed ID: 9546287
[TBL] [Abstract][Full Text] [Related]
12. APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.
Eisele G; Roth P; Hasenbach K; Aulwurm S; Wolpert F; Tabatabai G; Wick W; Weller M
Neuro Oncol; 2011 Feb; 13(2):155-64. PubMed ID: 21183510
[TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis.
Watson GA; Naran S; Zhang X; Stang MT; Queiroz de Oliveira PE; Hughes SJ
Neoplasia; 2011 Mar; 13(3):198-205. PubMed ID: 21390183
[TBL] [Abstract][Full Text] [Related]
14. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies.
Krendyukov A; Gieffers C
Cancer Manag Res; 2019; 11():8095-8100. PubMed ID: 31564969
[TBL] [Abstract][Full Text] [Related]
15. Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts.
Lang I; Fick A; Schäfer V; Giner T; Siegmund D; Wajant H
J Biol Chem; 2012 Jul; 287(28):24026-42. PubMed ID: 22645131
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study.
Yadav VN; Zamler D; Baker GJ; Kadiyala P; Erdreich-Epstein A; DeCarvalho AC; Mikkelsen T; Castro MG; Lowenstein PR
Oncotarget; 2016 Dec; 7(50):83701-83719. PubMed ID: 27863376
[TBL] [Abstract][Full Text] [Related]
17. CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation.
Nijkamp MW; Hoogwater FJ; Steller EJ; Westendorp BF; van der Meulen TA; Leenders MW; Borel Rinkes IH; Kranenburg O
J Hepatol; 2010 Dec; 53(6):1069-77. PubMed ID: 20832890
[TBL] [Abstract][Full Text] [Related]
18. Generation and Application of Bioluminescent CD95 Ligand Fusion Proteins.
Lang I; Kums J; Wajant H
Methods Mol Biol; 2017; 1557():63-77. PubMed ID: 28078583
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells.
Roth W; Wagenknecht B; Dichgans J; Weller M
J Neuroimmunol; 1998 Jul; 87(1-2):121-9. PubMed ID: 9670853
[TBL] [Abstract][Full Text] [Related]
20. Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells.
Roth W; Wild-Bode C; Platten M; Grimmel C; Melkonyan HS; Dichgans J; Weller M
Oncogene; 2000 Aug; 19(37):4210-20. PubMed ID: 10980594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
